Skip to main content
Clinical Trials/CTRI/2014/03/004494
CTRI/2014/03/004494
Active, Not Recruiting
N/A

Assessment of the effectiveness of prophylactic replacement of lower than ââ?¬Ë?standardââ?¬â?¢ doses of clotting factor concentrates in children with severe hemophilia A - MUSFIH-PRO

BAYER AWARD0 sites30 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Health Condition 1: null- HAEMOPHILIA A
Sponsor
BAYER AWARD
Enrollment
30
Status
Active, Not Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 1, 2019
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
BAYER AWARD

Eligibility Criteria

Inclusion Criteria

  • 1\. Severe hemophilia, defined as factor assay showing \<1% activity, between 3\-7 years of age
  • 2\. No single joint should have an HJHS score of more than 5\.
  • 3\. Not have detectable inhibitors by Bethesda assay ( \<0\.6 BU) at recruitment
  • 4\. Be willing to come for evaluation once in 9\-15 months for at least 2 (?4\) years. (in case
  • the study is extended)

Exclusion Criteria

  • PATIENTS WITH DOCUMENTED INHIBITORS.
  • NOT WILLING TO COME FOR FOLLOW UP FOR LONG TERM (ATLEAST 4 YEARS)

Outcomes

Primary Outcomes

Not specified

Similar Trials